Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
-
- Ayalew Tefferi
- Mayo Clinic, Rochester, MN;
-
- Francisco Cervantes
- Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain;
-
- Ruben Mesa
- Mayo Clinic, Scottsdale, AZ;
-
- Francesco Passamonti
- Ospedale di Circolo e Fondazione Macchi, Varese, Italy;
-
- Srdan Verstovsek
- MD Anderson Cancer Center, Houston, TX;
-
- Alessandro M. Vannucchi
- University of Florence, Florence, Italy;
-
- Jason Gotlib
- Stanford University School of Medicine, Stanford, CA;
-
- Brigitte Dupriez
- Service d'Hématologie Clinique, Centre Hospitalier de Lens, Lens, France;
-
- Animesh Pardanani
- Mayo Clinic, Rochester, MN;
-
- Claire Harrison
- Department of Haematology, St. Thomas Hospital, London, United Kingdom;
-
- Ronald Hoffman
- Mount Sinai School of Medicine, New York, NY;
-
- Heinz Gisslinger
- Medical University of Vienna, Vienna, Austria;
-
- Nicolaus Kröger
- University Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany;
-
- Juergen Thiele
- University of Cologne, Cologne, Germany;
-
- Tiziano Barbui
- Division of Hematology and Research Foundation, Ospedale Papa Giovanni XXIII, Bergamo, Italy; and
-
- Giovanni Barosi
- Center for the Study of Myelofibrosis, Biotechnology Research Area, Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation, Pavia, Italy
抄録
<jats:title>Key Points</jats:title> <jats:p>Treatment response criteria for MF must capture drug benefit in terms of symptom burden. The current document includes stricter definitions of red cell transfusion need and independence.</jats:p>
収録刊行物
-
- Blood
-
Blood 122 (8), 1395-1398, 2013-08-22
American Society of Hematology